nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Neurological symptom—Cisplatin—esophageal cancer	0.0263	0.0595	CcSEcCtD
Dicyclomine—Speech impairment NOS—Methotrexate—esophageal cancer	0.0199	0.0452	CcSEcCtD
Dicyclomine—Drug hypersensitivity—Capecitabine—esophageal cancer	0.0145	0.0329	CcSEcCtD
Dicyclomine—Sneezing—Capecitabine—esophageal cancer	0.0106	0.0239	CcSEcCtD
Dicyclomine—Necrosis—Cisplatin—esophageal cancer	0.0101	0.0229	CcSEcCtD
Dicyclomine—Ageusia—Cisplatin—esophageal cancer	0.00979	0.0222	CcSEcCtD
Dicyclomine—Thrombosis—Capecitabine—esophageal cancer	0.00826	0.0187	CcSEcCtD
Dicyclomine—Pain—Carboplatin—esophageal cancer	0.00825	0.0187	CcSEcCtD
Dicyclomine—Tingling sensation—Capecitabine—esophageal cancer	0.00727	0.0165	CcSEcCtD
Dicyclomine—Ageusia—Capecitabine—esophageal cancer	0.00722	0.0164	CcSEcCtD
Dicyclomine—Nasal congestion—Cisplatin—esophageal cancer	0.00632	0.0143	CcSEcCtD
Dicyclomine—Paralysis—Methotrexate—esophageal cancer	0.00626	0.0142	CcSEcCtD
Dicyclomine—Amnesia—Cisplatin—esophageal cancer	0.00613	0.0139	CcSEcCtD
Dicyclomine—Injection site reaction—Capecitabine—esophageal cancer	0.00581	0.0132	CcSEcCtD
Dicyclomine—Face oedema—Cisplatin—esophageal cancer	0.00556	0.0126	CcSEcCtD
Dicyclomine—Necrosis—Methotrexate—esophageal cancer	0.00555	0.0126	CcSEcCtD
Dicyclomine—Breast disorder—Cisplatin—esophageal cancer	0.0052	0.0118	CcSEcCtD
Dicyclomine—Apnoea—Methotrexate—esophageal cancer	0.00513	0.0116	CcSEcCtD
Dicyclomine—Speech disorder—Methotrexate—esophageal cancer	0.00506	0.0115	CcSEcCtD
Dicyclomine—Thrombophlebitis—Capecitabine—esophageal cancer	0.0049	0.0111	CcSEcCtD
Dicyclomine—Amnesia—Capecitabine—esophageal cancer	0.00452	0.0102	CcSEcCtD
Dicyclomine—Lethargy—Capecitabine—esophageal cancer	0.00433	0.00982	CcSEcCtD
Dicyclomine—Diplopia—Capecitabine—esophageal cancer	0.00424	0.00962	CcSEcCtD
Dicyclomine—Face oedema—Capecitabine—esophageal cancer	0.0041	0.00929	CcSEcCtD
Dicyclomine—Urinary retention—Capecitabine—esophageal cancer	0.00404	0.00915	CcSEcCtD
Dicyclomine—Mood swings—Capecitabine—esophageal cancer	0.00402	0.00912	CcSEcCtD
Dicyclomine—Breast disorder—Capecitabine—esophageal cancer	0.00384	0.00869	CcSEcCtD
Dicyclomine—Muscular weakness—Capecitabine—esophageal cancer	0.00374	0.00849	CcSEcCtD
Dicyclomine—Eye disorder—Cisplatin—esophageal cancer	0.00372	0.00844	CcSEcCtD
Dicyclomine—Cardiac disorder—Cisplatin—esophageal cancer	0.0037	0.00838	CcSEcCtD
Dicyclomine—Abdominal distension—Capecitabine—esophageal cancer	0.00369	0.00837	CcSEcCtD
Dicyclomine—Thrombophlebitis—Methotrexate—esophageal cancer	0.00365	0.00827	CcSEcCtD
Dicyclomine—Immune system disorder—Cisplatin—esophageal cancer	0.0036	0.00816	CcSEcCtD
Dicyclomine—Mediastinal disorder—Cisplatin—esophageal cancer	0.00359	0.00814	CcSEcCtD
Dicyclomine—Erythema—Cisplatin—esophageal cancer	0.00347	0.00786	CcSEcCtD
Dicyclomine—Vision blurred—Cisplatin—esophageal cancer	0.00327	0.00741	CcSEcCtD
Dicyclomine—Lethargy—Methotrexate—esophageal cancer	0.00322	0.00731	CcSEcCtD
Dicyclomine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00322	0.00729	CcSEcCtD
Dicyclomine—Malaise—Cisplatin—esophageal cancer	0.00313	0.00709	CcSEcCtD
Dicyclomine—Mood swings—Methotrexate—esophageal cancer	0.00299	0.00679	CcSEcCtD
Dicyclomine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00292	0.00662	CcSEcCtD
Dicyclomine—Discomfort—Cisplatin—esophageal cancer	0.00292	0.00661	CcSEcCtD
Dicyclomine—Breast disorder—Methotrexate—esophageal cancer	0.00286	0.00647	CcSEcCtD
Dicyclomine—Oedema—Cisplatin—esophageal cancer	0.00283	0.00642	CcSEcCtD
Dicyclomine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00283	0.00642	CcSEcCtD
Dicyclomine—Nervous system disorder—Cisplatin—esophageal cancer	0.00278	0.00629	CcSEcCtD
Dicyclomine—Tachycardia—Cisplatin—esophageal cancer	0.00276	0.00626	CcSEcCtD
Dicyclomine—Eye disorder—Capecitabine—esophageal cancer	0.00274	0.00622	CcSEcCtD
Dicyclomine—Cardiac disorder—Capecitabine—esophageal cancer	0.00272	0.00618	CcSEcCtD
Dicyclomine—Anorexia—Cisplatin—esophageal cancer	0.0027	0.00612	CcSEcCtD
Dicyclomine—Immune system disorder—Capecitabine—esophageal cancer	0.00265	0.00601	CcSEcCtD
Dicyclomine—Mediastinal disorder—Capecitabine—esophageal cancer	0.00265	0.006	CcSEcCtD
Dicyclomine—Mental disorder—Capecitabine—esophageal cancer	0.00257	0.00583	CcSEcCtD
Dicyclomine—Erythema—Capecitabine—esophageal cancer	0.00256	0.00579	CcSEcCtD
Dicyclomine—Paraesthesia—Cisplatin—esophageal cancer	0.00254	0.00576	CcSEcCtD
Dicyclomine—Dyspnoea—Cisplatin—esophageal cancer	0.00252	0.00572	CcSEcCtD
Dicyclomine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00251	0.0057	CcSEcCtD
Dicyclomine—Decreased appetite—Cisplatin—esophageal cancer	0.00246	0.00558	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00244	0.00554	CcSEcCtD
Dicyclomine—Drowsiness—Methotrexate—esophageal cancer	0.00243	0.00552	CcSEcCtD
Dicyclomine—Pain—Cisplatin—esophageal cancer	0.00242	0.00549	CcSEcCtD
Dicyclomine—Vision blurred—Capecitabine—esophageal cancer	0.00241	0.00546	CcSEcCtD
Dicyclomine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00237	0.00538	CcSEcCtD
Dicyclomine—Feeling abnormal—Cisplatin—esophageal cancer	0.00233	0.00529	CcSEcCtD
Dicyclomine—Malaise—Capecitabine—esophageal cancer	0.0023	0.00523	CcSEcCtD
Dicyclomine—Syncope—Capecitabine—esophageal cancer	0.00229	0.0052	CcSEcCtD
Dicyclomine—Palpitations—Capecitabine—esophageal cancer	0.00226	0.00512	CcSEcCtD
Dicyclomine—Loss of consciousness—Capecitabine—esophageal cancer	0.00225	0.00509	CcSEcCtD
Dicyclomine—Hypertension—Capecitabine—esophageal cancer	0.00221	0.005	CcSEcCtD
Dicyclomine—Discomfort—Capecitabine—esophageal cancer	0.00215	0.00487	CcSEcCtD
Dicyclomine—Dry mouth—Capecitabine—esophageal cancer	0.00213	0.00482	CcSEcCtD
Dicyclomine—Confusional state—Capecitabine—esophageal cancer	0.0021	0.00477	CcSEcCtD
Dicyclomine—Oedema—Capecitabine—esophageal cancer	0.00209	0.00473	CcSEcCtD
Dicyclomine—Hypersensitivity—Cisplatin—esophageal cancer	0.00208	0.00473	CcSEcCtD
Dicyclomine—Shock—Capecitabine—esophageal cancer	0.00205	0.00465	CcSEcCtD
Dicyclomine—Nervous system disorder—Capecitabine—esophageal cancer	0.00205	0.00464	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—esophageal cancer	0.00204	0.00463	CcSEcCtD
Dicyclomine—Tachycardia—Capecitabine—esophageal cancer	0.00204	0.00462	CcSEcCtD
Dicyclomine—Asthenia—Cisplatin—esophageal cancer	0.00203	0.0046	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—esophageal cancer	0.00203	0.0046	CcSEcCtD
Dicyclomine—Anorexia—Capecitabine—esophageal cancer	0.00199	0.00451	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—esophageal cancer	0.00197	0.00448	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—esophageal cancer	0.00197	0.00447	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—esophageal cancer	0.00191	0.00434	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—esophageal cancer	0.0019	0.00431	CcSEcCtD
Dicyclomine—Insomnia—Capecitabine—esophageal cancer	0.00189	0.00428	CcSEcCtD
Dicyclomine—Paraesthesia—Capecitabine—esophageal cancer	0.00187	0.00425	CcSEcCtD
Dicyclomine—Dyspnoea—Capecitabine—esophageal cancer	0.00186	0.00422	CcSEcCtD
Dicyclomine—Dyspepsia—Capecitabine—esophageal cancer	0.00184	0.00416	CcSEcCtD
Dicyclomine—Decreased appetite—Capecitabine—esophageal cancer	0.00181	0.00411	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0018	0.00408	CcSEcCtD
Dicyclomine—Vomiting—Cisplatin—esophageal cancer	0.0018	0.00408	CcSEcCtD
Dicyclomine—Fatigue—Capecitabine—esophageal cancer	0.0018	0.00408	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—esophageal cancer	0.00179	0.00407	CcSEcCtD
Dicyclomine—Rash—Cisplatin—esophageal cancer	0.00178	0.00405	CcSEcCtD
Dicyclomine—Constipation—Capecitabine—esophageal cancer	0.00178	0.00404	CcSEcCtD
Dicyclomine—Pain—Capecitabine—esophageal cancer	0.00178	0.00404	CcSEcCtD
Dicyclomine—Dermatitis—Cisplatin—esophageal cancer	0.00178	0.00404	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—esophageal cancer	0.00177	0.004	CcSEcCtD
Dicyclomine—Feeling abnormal—Capecitabine—esophageal cancer	0.00172	0.0039	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—esophageal cancer	0.00172	0.00389	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00171	0.00387	CcSEcCtD
Dicyclomine—Nausea—Cisplatin—esophageal cancer	0.00168	0.00381	CcSEcCtD
Dicyclomine—Urticaria—Capecitabine—esophageal cancer	0.00166	0.00376	CcSEcCtD
Dicyclomine—Abdominal pain—Capecitabine—esophageal cancer	0.00165	0.00374	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—esophageal cancer	0.0016	0.00363	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—esophageal cancer	0.00157	0.00355	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—esophageal cancer	0.00155	0.00352	CcSEcCtD
Dicyclomine—Hypersensitivity—Capecitabine—esophageal cancer	0.00154	0.00348	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—esophageal cancer	0.00152	0.00345	CcSEcCtD
Dicyclomine—Asthenia—Capecitabine—esophageal cancer	0.0015	0.00339	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—esophageal cancer	0.00148	0.00336	CcSEcCtD
Dicyclomine—Pruritus—Capecitabine—esophageal cancer	0.00148	0.00335	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—esophageal cancer	0.0014	0.00318	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—esophageal cancer	0.00139	0.00316	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—esophageal cancer	0.00138	0.00314	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—esophageal cancer	0.00138	0.00313	CcSEcCtD
Dicyclomine—Dizziness—Capecitabine—esophageal cancer	0.00138	0.00313	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—esophageal cancer	0.00137	0.0031	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—esophageal cancer	0.00135	0.00306	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00134	0.00304	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—esophageal cancer	0.00134	0.00304	CcSEcCtD
Dicyclomine—Pain—Methotrexate—esophageal cancer	0.00133	0.00301	CcSEcCtD
Dicyclomine—Vomiting—Capecitabine—esophageal cancer	0.00133	0.00301	CcSEcCtD
Dicyclomine—Rash—Capecitabine—esophageal cancer	0.00132	0.00298	CcSEcCtD
Dicyclomine—Dermatitis—Capecitabine—esophageal cancer	0.00131	0.00298	CcSEcCtD
Dicyclomine—Headache—Capecitabine—esophageal cancer	0.00131	0.00296	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—esophageal cancer	0.00128	0.0029	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00127	0.00288	CcSEcCtD
Dicyclomine—Nausea—Capecitabine—esophageal cancer	0.00124	0.00281	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—esophageal cancer	0.00123	0.0028	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—esophageal cancer	0.00123	0.00278	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—esophageal cancer	0.00114	0.00259	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—esophageal cancer	0.00111	0.00253	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—esophageal cancer	0.0011	0.00249	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—esophageal cancer	0.00103	0.00233	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—esophageal cancer	0.000987	0.00224	CcSEcCtD
Dicyclomine—Rash—Methotrexate—esophageal cancer	0.000979	0.00222	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—esophageal cancer	0.000978	0.00222	CcSEcCtD
Dicyclomine—Headache—Methotrexate—esophageal cancer	0.000973	0.00221	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—esophageal cancer	0.000922	0.00209	CcSEcCtD
Dicyclomine—CYP1A1—PPARA activates gene expression—EP300—esophageal cancer	0.000588	0.00105	CbGpPWpGaD
Dicyclomine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—esophageal cancer	0.000582	0.00104	CbGpPWpGaD
Dicyclomine—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—esophageal cancer	0.000575	0.00103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KMT2D—esophageal cancer	0.000558	0.000998	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KMT2D—esophageal cancer	0.000556	0.000995	CbGpPWpGaD
Dicyclomine—CHRM2—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000554	0.000991	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—SLC52A3—esophageal cancer	0.000554	0.000991	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—BLVRB—esophageal cancer	0.000554	0.000991	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KMT2D—esophageal cancer	0.000551	0.000985	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000546	0.000977	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PDE4D—esophageal cancer	0.000545	0.000974	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKAP13—esophageal cancer	0.000542	0.000971	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CA2—esophageal cancer	0.000542	0.00097	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKAP13—esophageal cancer	0.000541	0.000967	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000539	0.000965	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKAP13—esophageal cancer	0.000535	0.000958	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—GNG7—esophageal cancer	0.00052	0.00093	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—GNG7—esophageal cancer	0.000518	0.000927	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—GNG7—esophageal cancer	0.000513	0.000918	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ADH7—esophageal cancer	0.000504	0.000902	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PLCE1—esophageal cancer	0.000504	0.000902	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000497	0.00089	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PDE4D—esophageal cancer	0.000496	0.000888	CbGpPWpGaD
Dicyclomine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	0.000496	0.000888	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ADCYAP1—esophageal cancer	0.000496	0.000887	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000495	0.000886	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PDE4D—esophageal cancer	0.000495	0.000885	CbGpPWpGaD
Dicyclomine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	0.000495	0.000885	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000491	0.000878	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PDE4D—esophageal cancer	0.00049	0.000876	CbGpPWpGaD
Dicyclomine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—esophageal cancer	0.00049	0.000876	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—GNG7—esophageal cancer	0.000472	0.000844	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CA1—esophageal cancer	0.000471	0.000843	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—SLC10A2—esophageal cancer	0.000471	0.000843	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—GNG7—esophageal cancer	0.00047	0.000842	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—GNG7—esophageal cancer	0.000466	0.000833	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—EP300—esophageal cancer	0.000458	0.00082	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000458	0.000819	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—CXCL2—esophageal cancer	0.000456	0.000817	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—WWOX—esophageal cancer	0.000455	0.000814	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—WWOX—esophageal cancer	0.000453	0.000811	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000452	0.000809	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—WWOX—esophageal cancer	0.000449	0.000803	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ADH1B—esophageal cancer	0.000442	0.000791	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FKBP1A—esophageal cancer	0.000433	0.000774	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FKBP1A—esophageal cancer	0.000431	0.000772	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CA2—esophageal cancer	0.000431	0.000771	CbGpPWpGaD
Dicyclomine—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	0.000431	0.00077	CbGpPWpGaD
Dicyclomine—CHRM3—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	0.000429	0.000768	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FKBP1A—esophageal cancer	0.000427	0.000764	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000426	0.000762	CbGpPWpGaD
Dicyclomine—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—esophageal cancer	0.000425	0.00076	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—ANXA1—esophageal cancer	0.000424	0.000759	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—WIF1—esophageal cancer	0.000423	0.000757	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—TYMP—esophageal cancer	0.000422	0.000756	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—WIF1—esophageal cancer	0.000421	0.000754	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000421	0.000753	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—ANXA1—esophageal cancer	0.00042	0.000752	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—WIF1—esophageal cancer	0.000417	0.000747	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL2—esophageal cancer	0.000416	0.000744	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL2—esophageal cancer	0.000414	0.000741	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—SST—esophageal cancer	0.000414	0.000741	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—SST—esophageal cancer	0.000413	0.000738	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP26A1—esophageal cancer	0.000411	0.000735	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL2—esophageal cancer	0.00041	0.000734	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—SST—esophageal cancer	0.000409	0.000731	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—GHRL—esophageal cancer	0.000403	0.000722	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—GHRL—esophageal cancer	0.000402	0.00072	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALOX15—esophageal cancer	0.0004	0.000716	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ADH7—esophageal cancer	0.0004	0.000716	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PLCE1—esophageal cancer	0.0004	0.000716	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—GHRL—esophageal cancer	0.000398	0.000713	CbGpPWpGaD
Dicyclomine—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—esophageal cancer	0.000396	0.000709	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000396	0.000708	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CSNK1A1—esophageal cancer	0.00039	0.000698	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000389	0.000696	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—ANXA1—esophageal cancer	0.000387	0.000692	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—ANXA1—esophageal cancer	0.000385	0.000689	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000385	0.000689	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GSTO1—esophageal cancer	0.000382	0.000683	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—TPI1—esophageal cancer	0.000382	0.000683	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—ANXA1—esophageal cancer	0.000382	0.000683	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—SST—esophageal cancer	0.000376	0.000673	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—SST—esophageal cancer	0.000375	0.000671	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—SST—esophageal cancer	0.000371	0.000664	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00037	0.000662	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000369	0.00066	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—GHRL—esophageal cancer	0.000366	0.000656	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALDOB—esophageal cancer	0.000366	0.000655	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—GHRL—esophageal cancer	0.000365	0.000653	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PFN1—esophageal cancer	0.000365	0.000653	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PFN1—esophageal cancer	0.000364	0.000651	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—GHRL—esophageal cancer	0.000362	0.000647	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PFN1—esophageal cancer	0.00036	0.000645	CbGpPWpGaD
Dicyclomine—CHRM1—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000359	0.000642	CbGpPWpGaD
Dicyclomine—CHRM3—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000358	0.00064	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GAPDH—esophageal cancer	0.000353	0.000631	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ADH1B—esophageal cancer	0.000351	0.000628	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CRABP1—esophageal cancer	0.000349	0.000625	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TYMP—esophageal cancer	0.000336	0.0006	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GNG7—esophageal cancer	0.000332	0.000595	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000328	0.000587	CbGpPWpGaD
Dicyclomine—CHRM1—Circadian rythm related genes—TP53—esophageal cancer	0.000328	0.000587	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ELMO1—esophageal cancer	0.000327	0.000585	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP26A1—esophageal cancer	0.000326	0.000584	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ELMO1—esophageal cancer	0.000324	0.000579	CbGpPWpGaD
Dicyclomine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000321	0.000575	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKAP13—esophageal cancer	0.00032	0.000573	CbGpPWpGaD
Dicyclomine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.00032	0.000573	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKAP13—esophageal cancer	0.000319	0.000571	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALOX15—esophageal cancer	0.000318	0.000569	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKAP13—esophageal cancer	0.000316	0.000566	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALDH2—esophageal cancer	0.000311	0.000557	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TPI1—esophageal cancer	0.000303	0.000543	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTO1—esophageal cancer	0.000303	0.000543	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—GSTT1—esophageal cancer	0.000296	0.00053	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000296	0.000529	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000295	0.000527	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PDE4D—esophageal cancer	0.000293	0.000524	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP2A6—esophageal cancer	0.000293	0.000524	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PDE4D—esophageal cancer	0.000292	0.000523	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000292	0.000522	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALDOB—esophageal cancer	0.000291	0.000521	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PDE4D—esophageal cancer	0.000289	0.000518	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GAPDH—esophageal cancer	0.00028	0.000501	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GNG7—esophageal cancer	0.000279	0.000499	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GNG7—esophageal cancer	0.000278	0.000497	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ENO1—esophageal cancer	0.000278	0.000497	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS1—esophageal cancer	0.000278	0.000497	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CRABP1—esophageal cancer	0.000278	0.000497	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GNG7—esophageal cancer	0.000275	0.000492	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PSME2—esophageal cancer	0.000273	0.000489	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PSME1—esophageal cancer	0.000273	0.000489	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GNG7—esophageal cancer	0.000264	0.000472	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—XIAP—esophageal cancer	0.000261	0.000467	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—XIAP—esophageal cancer	0.00026	0.000466	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—XIAP—esophageal cancer	0.000258	0.000461	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALDH2—esophageal cancer	0.000247	0.000443	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000247	0.000442	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CTNNA1—esophageal cancer	0.000246	0.000441	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000246	0.000439	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL2—esophageal cancer	0.000245	0.000438	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CTNNA1—esophageal cancer	0.000244	0.000436	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL2—esophageal cancer	0.000242	0.000434	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP1B1—esophageal cancer	0.000236	0.000422	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTT1—esophageal cancer	0.000235	0.000421	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP2A6—esophageal cancer	0.000233	0.000416	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000232	0.000415	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PSME2—esophageal cancer	0.000229	0.00041	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PSME1—esophageal cancer	0.000229	0.00041	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PSME1—esophageal cancer	0.000229	0.000409	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PSME2—esophageal cancer	0.000229	0.000409	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000228	0.000409	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ANXA1—esophageal cancer	0.000228	0.000407	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PSME1—esophageal cancer	0.000226	0.000405	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PSME2—esophageal cancer	0.000226	0.000405	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ANXA1—esophageal cancer	0.000225	0.000403	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SST—esophageal cancer	0.000222	0.000397	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CYP19A1—esophageal cancer	0.000222	0.000397	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SST—esophageal cancer	0.000221	0.000396	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS1—esophageal cancer	0.00022	0.000395	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ENO1—esophageal cancer	0.00022	0.000395	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SST—esophageal cancer	0.000219	0.000392	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PSME1—esophageal cancer	0.000217	0.000389	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PSME2—esophageal cancer	0.000217	0.000389	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—GHRL—esophageal cancer	0.000216	0.000387	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.000216	0.000387	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—GHRL—esophageal cancer	0.000216	0.000386	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH3—esophageal cancer	0.000216	0.000386	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH3—esophageal cancer	0.000214	0.000382	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—GHRL—esophageal cancer	0.000214	0.000382	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000213	0.000381	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FBXW7—esophageal cancer	0.000212	0.00038	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FBXW7—esophageal cancer	0.00021	0.000376	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—HMOX1—esophageal cancer	0.000202	0.000362	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ABCB1—esophageal cancer	0.000194	0.000348	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000194	0.000347	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH2—esophageal cancer	0.000194	0.000346	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH2—esophageal cancer	0.000192	0.000343	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.00019	0.000339	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP1B1—esophageal cancer	0.000187	0.000335	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CYP19A1—esophageal cancer	0.000176	0.000315	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000172	0.000308	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFBR2—esophageal cancer	0.000172	0.000307	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFBR2—esophageal cancer	0.00017	0.000304	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SMAD4—esophageal cancer	0.000163	0.000292	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SMAD4—esophageal cancer	0.000163	0.000291	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SMAD4—esophageal cancer	0.000161	0.000288	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—HMOX1—esophageal cancer	0.000161	0.000288	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000158	0.000282	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ABCB1—esophageal cancer	0.000154	0.000276	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—esophageal cancer	0.000133	0.000239	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—esophageal cancer	0.000133	0.000238	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—esophageal cancer	0.000132	0.000236	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CREBBP—esophageal cancer	0.00013	0.000232	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—esophageal cancer	0.000128	0.000228	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—esophageal cancer	0.000127	0.000228	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—esophageal cancer	0.000126	0.000225	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH1—esophageal cancer	0.00012	0.000215	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH1—esophageal cancer	0.00012	0.000214	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH1—esophageal cancer	0.000119	0.000212	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	0.000117	0.000209	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—NOS3—esophageal cancer	0.000116	0.000208	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CREBBP—esophageal cancer	0.000109	0.000195	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CREBBP—esophageal cancer	0.000109	0.000194	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CREBBP—esophageal cancer	0.000108	0.000192	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—esophageal cancer	0.000107	0.000192	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—esophageal cancer	0.000107	0.000191	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—esophageal cancer	0.000106	0.00019	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—esophageal cancer	0.000106	0.000189	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CREBBP—esophageal cancer	0.000103	0.000185	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000102	0.000183	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000102	0.000182	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000101	0.000181	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOS3—esophageal cancer	9.76e-05	0.000175	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOS3—esophageal cancer	9.72e-05	0.000174	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOS3—esophageal cancer	9.63e-05	0.000172	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—esophageal cancer	9.29e-05	0.000166	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—esophageal cancer	9.26e-05	0.000166	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—NOS3—esophageal cancer	9.24e-05	0.000165	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—esophageal cancer	9.17e-05	0.000164	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB2—esophageal cancer	9.12e-05	0.000163	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB2—esophageal cancer	9.1e-05	0.000163	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB2—esophageal cancer	9.01e-05	0.000161	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—EP300—esophageal cancer	8.85e-05	0.000158	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—esophageal cancer	8.45e-05	0.000151	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—esophageal cancer	8.06e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—esophageal cancer	8.04e-05	0.000144	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—esophageal cancer	7.96e-05	0.000142	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—esophageal cancer	7.8e-05	0.00014	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—esophageal cancer	7.77e-05	0.000139	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—esophageal cancer	7.7e-05	0.000138	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EP300—esophageal cancer	7.42e-05	0.000133	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EP300—esophageal cancer	7.4e-05	0.000132	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EP300—esophageal cancer	7.33e-05	0.000131	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—EP300—esophageal cancer	7.03e-05	0.000126	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—esophageal cancer	6.54e-05	0.000117	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—esophageal cancer	6.47e-05	0.000116	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—esophageal cancer	6.45e-05	0.000115	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—esophageal cancer	6.38e-05	0.000114	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—esophageal cancer	6.32e-05	0.000113	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—esophageal cancer	6.3e-05	0.000113	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—esophageal cancer	6.24e-05	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—esophageal cancer	5.49e-05	9.82e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—esophageal cancer	5.47e-05	9.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—esophageal cancer	5.42e-05	9.69e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—esophageal cancer	5.31e-05	9.5e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—esophageal cancer	5.29e-05	9.47e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—esophageal cancer	5.24e-05	9.38e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—esophageal cancer	5.2e-05	9.3e-05	CbGpPWpGaD
